GSK — Pharmaceutical Intelligence | Humanexa Signals

ClinicalJuly 11, 2026

GSK's Mo-Rez Evaluated in 1L Maintenance for HRd Ovarian Cancer in BEHOLD-Ovarian03 Trial

The BEHOLD-Ovarian03 trial is assessing the efficacy and safety of mocertatug rezetecan (Mo-Rez) in combination with bevacizumab versus bevacizumab alone in first-line maintenance treatment of HRd ovarian cancer.

Recent signals(19)

First-in-Human Trial for GSK4425689A Monoclonal Antibody Initiated

FDA Approves Supplemental Application for Brexafemme (Ibrexafungerp) by GlaxoSmithKline

FDA Accepts Supplement for Brexafemme (Ibrexafungerp) by GlaxoSmithKline

Upcoming catalysts

Regulatory activity(9)

FDA Approves Supplemental Application for Brexafemme (Ibrexafungerp) by GlaxoSmithKline

FDA Accepts Supplement for Brexafemme (Ibrexafungerp) by GlaxoSmithKline

FDA Accepts Supplemental Application for ZYBAN by GlaxoSmithKline

Clinical activity(6)

GSK Initiates First-Time-in-Human Study of Remzistotug for Advanced Solid Tumors

GSK's Bepirovirsen Study Targets HIV/HBV Co-Infection Efficacy and Safety

GSK's Mo-Rez Evaluated in 1L Maintenance for HRd Ovarian Cancer in BEHOLD-Ovarian03 Trial

Competitive activity(2)

First-in-Human Trial for GSK4425689A Monoclonal Antibody Initiated

Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough

Assets

Therapeutic areas

Indications

Get signals before the market moves

FDA Accepts Supplemental Application for ZYBAN by GlaxoSmithKline

FDA Accepts Supplement for OJJAARA (Momelotinib Dihydrochloride) by GlaxoSmithKline

FDA Approves Supplemental Applications for ZYBAN by GlaxoSmithKline

GSK Initiates First-Time-in-Human Study of Remzistotug for Advanced Solid Tumors

GSK's Bepirovirsen Study Targets HIV/HBV Co-Infection Efficacy and Safety

Phase II Trial Shows Comparable Immunogenicity of GSK's Investigational MMRV Vaccine

GSK's Bepirovirsen Study Evaluates Cardiac Conduction Impact in Healthy Volunteers

GSK's Mo-Rez Evaluated in 1L Maintenance for HRd Ovarian Cancer in BEHOLD-Ovarian03 Trial

Phase III Trial Shows Non-Inferior Immunogenicity of PCV-Free Rotavirus Vaccine in Infants

GSK's Belantamab Mafodotin Study Targets Multiple Myeloma with Renal Impairment

FDA Grants Priority Review for UTEBZI (TEBIPENEM, PIVOXIL) by GlaxoSmithKline

FDA Accepts Supplement Application for Depemokimab by GlaxoSmithKline

FDA Accepts Supplemental Application for Malarone Pediatric

OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients

Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough

GSK's AS03-adjuvanted H5N8 vaccine shows promising immunogenicity and safety in Phase 1/2 trial

FDA Accepts Supplement for OJJAARA (Momelotinib Dihydrochloride) by GlaxoSmithKline

FDA Approves Supplemental Applications for ZYBAN by GlaxoSmithKline

GSK's Bepirovirsen Study Evaluates Cardiac Conduction Impact in Healthy Volunteers

FDA Grants Priority Review for UTEBZI (TEBIPENEM, PIVOXIL) by GlaxoSmithKline

FDA Accepts Supplement Application for Depemokimab by GlaxoSmithKline

FDA Accepts Supplemental Application for Malarone Pediatric

GSK's Belantamab Mafodotin Study Targets Multiple Myeloma with Renal Impairment

OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients

GSK's AS03-adjuvanted H5N8 vaccine shows promising immunogenicity and safety in Phase 1/2 trial